|
Hyperuricemia
|
0.210 |
Biomarker
|
disease |
BEFREE |
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
|
30951542 |
2019 |
|
Chronic Kidney Diseases
|
0.120 |
Biomarker
|
group |
BEFREE |
Further clinical studies are warranted with a broader range of OCT2 substrates to determine whether CKD may differentially affect tubular secretion of drugs especially in patients with advanced CKD.
|
28483424 |
2017 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
BEFREE |
Follow-up of the 23 new genome-wide-significant loci (P < 5 x 10(-8)) in 22,982 replication samples identified 13 new loci affecting renal function and CKD (in or near LASS2, GCKR, ALMS1, TFDP2, DAB2, SLC34A1, VEGFA, PRKAG2, PIP5K1B, ATXN2, DACH1, UBE2Q2 and SLC7A9) and 7 loci suspected to affect creatinine production and secretion (CPS1, SLC22A2, TMEM60, WDR37, SLC6A13, WDR72 and BCAS3).
|
20383146 |
2010 |
|
Diabetes Mellitus
|
0.110 |
Biomarker
|
group |
BEFREE |
We investigated the influence of diabetes mellitus (DM), glycemic control with insulin, cimetidine (Oct2 inhibitor) and metformin (Oct2 substrate) on the kinetic disposition of GAB in rats.
|
29551575 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The SLC22A2 single nucleotide polymorphism (SNP) 808G/T was genotyped in 400 T2DM patients, including a metformin-treated group (n=200) and a non-metformin-treated group (n=200).
|
20139901 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.
|
27609360 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined the role of OCT2-T201M (602 C>T) variant in insulin resistance in patients with type 2 diabetes (T2D) who were treated with metformin.
|
25662675 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
As well as gender, the glucose-lowering efficiency of metformin can be enhanced by SLC22A2 808G > T variants through the delay of its transportation and CLr in Chinese type 2 diabetes populations.
|
25573751 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate whether genetic variations in the SLC22A1, SLC22A2, and SLC47A1 genes could be associated with an altered response to metformin in patients with type 2 diabetes mellitus.
|
31012983 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporters-solute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes.
|
22882994 |
2013 |
|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
We conclude that the expression pattern of OCT2, SSX2-4, and SAGE1 supports the origin of SS from spermatogonia and provides new evidence for heterogeneity of this tumour, potentially linked either to the cellular origin of SS or to partial differentiation during tumour progression, including a hitherto unknown OCT2-positive variant of the tumour likely derived from A(dark) spermatogonia.
|
21706474 |
2011 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Mouse splenic and thymic lymphocytes and tumor tissues were analyzed for the expression of cytokines involved in inflammatory and immune responses, including tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), basic fibroblast growth factor (bFGF), and interleukin 12 (IL-12); for the activation of the transcription factors nuclear factor-kappaB (NF-kappaB) and the B cell-specific transcription factor Oct-2; and for the activation of the Src and Syk family kinases, components of B-cell receptor-induced signal-transduction pathways.
|
12072546 |
2002 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
OCT-2 immunostaining was primarily restricted in normal lymphoid tissue to B cells, and was absent from most T-cell neoplasms.
|
12598320 |
2003 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
However, expressions of Oct-2 and CD10 in the relapse tumor were both more compatible with B cell than PDC lineage.
|
19504395 |
2009 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Exemplarily, gene-specific analyses of DNA methylation, mRNA and protein expression demonstrate lack of expression of the clinically important drug transporter OCT2 (encoded by SLC22A2) in cell lines due to hypermethylation compared to tumors or metastases.
|
27435027 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using a randomized crossover design and continuous variables such as change in hearing threshold and biomarkers of acute renal injury as short-term endpoints, it was determined that pantoprazole, an organic cation transporter 2 inhibitor, did not ameliorate cisplatin-associated nephrotoxicity or ototoxicity.Cystatin C is a robust method to estimate glomerular filtration rate in patients with cancer.
|
29445029 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Using data obtained from the cancer transcriptome database Oncomine and the proteome database The Human Protein Atlas, we identified the repression of organic cation transporter OCT2 as a potential factor contributing to oxaliplatin resistance in RCC.
|
27440728 |
2016 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Collectively, these preclinical data provide evidence for a direct effect of metformin <i>in vivo</i> and suggest that OCT2 expression may predict metformin uptake and tumor response.<i>Cancer </i>.
|
28154203 |
2017 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
|
22223530 |
2012 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.
|
11154228 |
2001 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
To check the genomic status of PU.1, BOB1, and OCT2 in HL, we performed metaphase fluorescence in situ hybridization (FISH) analysis of 10 HL cases using locus-specific bacterial artificial chromosome clones.
|
15796964 |
2005 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Seven different cell lines derived from patients with Hodgkin's disease (HD), as well as primary H/Reed-Sternberg (RS) cells isolated from the pericardial fluid of a patient with HD, were compared with a number of hematopoietic and nonhematopoietic cell lines for the expression of Oct-2, a tissue-specific transcription factor normally restricted to B cells, and nuclear factor kappa B (NF-kappa B), an inducible transcription factor.
|
8639794 |
1996 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Absence of Oct-2 and Bob-1 protein expression in primary H-RS cells was demonstrated by performing immunohistochemistry in 20 cases of classical Hodgkin's disease.
|
11280769 |
2001 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Oct2 was expressed strongly in 12 of 16 AML cases with t(8;21) and 19 of 46 without t(8;21).
|
16891199 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Although OCT-2 and BOB.1 were not associated with PAX5 expression, we report expression of OCT-2 in AML with myelomonocytic/monocytic maturation and BOB.1 in normal hematopoietic elements.
|
17074681 |
2006 |